(Q44148231)

30 November 2017

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

30 November 2017

0 references

1 reference

6

1 reference

30 November 2017

Ansari A

1

1 reference

30 November 2017

Hassan C

2

1 reference

30 November 2017

Duley J

3

1 reference

30 November 2017

Marinaki A

4

1 reference

30 November 2017

Shobowale-Bakre EM

5

1 reference

30 November 2017

Meenan J

7

1 reference

30 November 2017

Yim A

8

1 reference

30 November 2017

Sanderson J

9

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Alimentary Pharmacology & Therapeutics

30 November 2017

1 reference

30 November 2017

16

1 reference

30 November 2017

10

1 reference

30 November 2017

1743-1750

1 reference

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

30 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

Thiopurine methyltransferase alleles in British and Ghanaian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01353.X

10.1046/J.1365-2036.2002.01353.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference